Chronic wounds represent a disproportionate burden on the U.S. health care system, affecting an estimated 6.5 million patients and costing over $50 billion annually, according to actual reimbursement data from the US Wound Registry.

The magnitude of wound care problem globally can reliably be expected to grow at a faster rate due to the convergence of five major epidemiologic factors: burgeoning aging population, rising incidence of diabetes, obesity epidemic, mutating drug-resistant microbes, and a virtually dry antibiotic pipeline. There are one million amputations per year globally, and one every 20 seconds due to diabetes.

While many wound care products (from advanced dressings to NPWT devices) exist on the market, none is able to sufficiently overcome the impoverished blood flow and tissue oxygenation—the two biggest challenges facing chronic wounds—to enable healing faster than the current average time of nearly 6 months. Wound care therefore continues to be a serious, growing problem for patients, healthcare professionals and facilities, government, and third-party payers.

HealO Medical has developed technologies that are exceptionally effective in reversing hypoxia and hypoperfusion while eliminating tedious nursing care, pain, and suffering. Our mission is to deliver faster healing, reduce suffering, and cut healthcare costs.

HealO’s patented and patent pending ClearHeal^® clear-view wound healing chambers, and BeneHeal^® super dressings, in conjunction with O-ACE-Sys^®, our proprietary smart control module, enable custom delivery of a variety of therapeutics (including proteolytic enzyme soaks, antibiotic lavage, analgesic instillation, etc.) directly to the wound site. The platform also provides an optimized micro-environment for the incubation of high-value bioengineered materials (stem cells, tissue grafts, growth factors, etc.).

O-ACE-Sys^® is a patented, integrated, multi-modal therapeutic delivery platform designed to accelerate the healing of chronic and acute wounds.

“Your device has significant promise to advance wound care. The savings to the healthcare system cannot be over emphasized.”
David Armstrong, DPM, MD, PhD, Professor of Surgery and Director, Southwestern Academic Limb Salvage Alliance (SALSA) at Keck School of Medicine, University of Southern California

“There is a great need for an intelligent and innovative system, such as yours. Being able to combine and automate an optimum regimen of therapies without close attention from a physician and nurse is a great advance made possible by creative combination of sound pathology principles and innovative engineering. These unique qualities make the O-ACE-Sys best-in-class.”
H. Peter Lorenz, MD, Professor of Plastic Surgery, Chief, Pediatric Plastic Surgery, Lucile Packard Children’s Hospital, Hagey Laboratory for Pediatric Regenerative Medicine, Stanford University School of Medicine

“The goal for our patients is simple – safely heal the wound in the shortest possible time AND at an affordable price. I believe the O-ACE-Sys wound treatment system will help to achieve these goals.”
Ronald G. Scott, Director Emeritus, The Wound Care Clinics of North Texas, The Medical Center of Plano, CTO, WoundWoRx

“I think this device has very exciting potential and would have great use particularly in smaller burns and skin grafts.”
Sidney F. Miller, MD, FACS, Director OSU Burn Center; Professor of Surgery at The Ohio State University and former President, American Burn Association (2011)

“I’m convinced that O-ACE-Sys will be able to deliver a comprehensive range of treatments and provide more rapid recovery than the chronic wound care system.”
Risal S. Djohan, MD, Head, Regional Medical Practice for Plastic Surgery, Cleveland Clinic

“Innovative may be an understatement for the O-ACE-Sys as it is truly revolutionary. The O-ACE-Sys provides the first that multimodality care may be directly delivered to the wound.”
Jonathan C. Fong, MD, Cardiovascular Surgeon at First Physicians Group at Sarasota Memorial Hospital.